Full Press Release Details
SAN FRANCISCO,May 27, 2026/PRNewswire/ -- Nektar Therapeutics (Nasdaq:NKTR) today announced that company management will be webcasting its participation in the 2026 Jefferies Global Healthcare Conference being held June 2-4, 2026 in New York.
• 2026 Jefferies Global Healthcare Conference in New York on Wednesday, June 3, 2026 – webcast to be available at 1:20 p.m. Eastern Time – webcast linkhere
The fireside chat will be accessible via the webcast link above as well as on the Investor Events section of the Nektar website:https://ir.nektar.com/events-and-presentations/events. A replay of the fireside chat will be available for 30 days.
If you would like to request a one-on-one meeting with company management during the conference, please reach out to your respective representative.
About Nektar Therapeutics
Nektar Therapeutics is a clinical-stage biotechnology company focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases. Nektar's lead product candidate, rezpegaldesleukin (REZPEG, or NKTR-358), is a novel, first-in-class regulatory T cell stimulator being evaluated in one Phase 2b clinical trial in atopic dermatitis, one Phase 2b clinical trial in alopecia areata, and in one Phase 2 clinical trial in Type 1 diabetes mellitus. Nektar's pipeline also includes a preclinical bivalent tumor necrosis factor receptor type II (TNFR2) antibody and bispecific programs, NKTR-0165 and NKTR-0166, and a modified hematopoietic colony stimulating factor (CSF) protein, NKTR-422.
Nektar is headquartered in San Francisco, California. For further information, visitwww.nektar.comand follow us on LinkedIn.
For Investors:
Vivian Wu628-895-0661[email protected]
Corey Davis, Ph.D.LifeSci Advisors212-915-2577[email protected]